Drug Profile
ST 36
Alternative Names: ST-36Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Columbia University
- Developer Sapience Therapeutics
- Class Antineoplastics; Peptides
- Mechanism of Action Activating transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma; Neuroblastoma
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Glioblastoma in USA (unspecified route) (Sapience Therapeutics pipeline, September 2023)
- 06 Sep 2023 Discontinued - Preclinical for Neuroblastoma in USA (unspecified route) (Sapience Therapeutics pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Glioblastoma in USA